SHADE-AD: An LLM-Based Framework for Synthesizing Activity Data of Alzheimer's Patients

Alzheimer's Disease (AD) has become an increasingly critical global health concern, which necessitates effective monitoring solutions in smart health applications. However, the development of such solutions is significantly hindered by the scarcity of AD-specific activity datasets. To address this challenge, we propose SHADE-AD, a Large Language Model (LLM) framework for Synthesizing Human Activity Datasets Embedded with AD features. Leveraging both public datasets and our own collected data from 99 AD patients, SHADE-AD synthesizes human activity videos that specifically represent AD-related behaviors. By employing a three-stage training mechanism, it broadens the range of activities beyond those collected from limited deployment settings. We conducted comprehensive evaluations of the generated dataset, demonstrating significant improvements in downstream tasks such as Human Activity Recognition (HAR) detection, with enhancements of up to 79.69%. Detailed motion metrics between real and synthetic data show strong alignment, validating the realism and utility of the synthesized dataset. These results underscore SHADE-AD's potential to advance smart health applications by providing a cost-effective, privacy-preserving solution for AD monitoring.

ADMarker: A Multi-Modal Federated Learning System for Monitoring Digital Biomarkers of Alzheimer's Disease

Alzheimer's Disease (AD) and related dementia are a growing global health challenge due to the aging population. In this paper, we present ADMarker, the first end-to-end system that integrates multi-modal sensors and new federated learning algorithms for detecting multidimensional AD digital biomarkers in natural living environments. ADMarker features a novel three-stage multi-modal federated learning architecture that can accurately detect digital biomarkers in a privacy-preserving manner. Our approach collectively addresses several major real-world challenges, such as limited data labels, data heterogeneity, and limited computing resources. We built a compact multi-modality hardware system and deployed it in a four-week clinical trial involving 91 elderly participants. The results indicate that ADMarker can accurately detect a comprehensive set of digital biomarkers with up to 93.8% accuracy and identify early AD with an average of 88.9% accuracy. ADMarker offers a new platform that can allow AD clinicians to characterize and track the complex correlation between multidimensional interpretable digital biomarkers, demographic factors of patients, and AD diagnosis in a longitudinal manner.